Pamicell and Wonju Yonsei Medical Center Joint Symposium on Regenerative Medicine

[Asia Economy Reporter Hyungsoo Park] Pamicell announced on the 23rd that the 'Yonsei University Institute for Regenerative Medicine-Pamicell Symposium' concluded successfully.

At the symposium co-hosted by Yonsei University Institute for Regenerative Medicine and Pamicell, an interim presentation on the joint research agreement for mesenchymal stem cell analysis signed last January was given, along with sharing information on the treatment progress of stem cell therapeutics and production technology for raw materials used in manufacturing messenger RNA (mRNA) vaccines.

In the first session, presentations were made on the interim results of identifying biomarkers related to cardiovascular disease genes and the establishment of an artificial intelligence big data environment to support genomic analysis.

Professor Taesik Lee of Wonju Severance Christian Hospital stated, "Through analysis of blood transcriptome data collected from public data, we identified candidate genes related to cardiovascular diseases," adding, "We will sequentially continue to discover biomarkers that can predict stem cell treatment responses using this data."

In the second session, presentations were given on 'Clinical Experience in Treating Liver Cirrhosis Using Stem Cell Therapeutics' and 'Development of GMP-grade Production Technology for High-purity Nucleotides for mRNA Vaccine Manufacturing.'

Hyunsoo Kim, CEO of Pamicell, said, "In the Phase 2 clinical trial of Cellgram-LC, comparing data before and after administration of the therapeutic, we confirmed improvements in the degree of liver fibrosis and Child-Pugh scores two months after administration." He added, "Stem cell therapeutics can be an effective treatment alternative for patients who have difficulty undergoing liver transplantation."

A Pamicell representative introduced, "Research is progressing smoothly not only in the bio business division but also in the chemical business division," and "We are participating in projects to develop manufacturing processes for core raw and subsidiary materials of mRNA, researching competitive production technologies." They also stated, "The development of dNTP, a core raw material for molecular diagnostics, has entered its final stages."